Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype.

Čipak Gašparović A, Milković L, Dandachi N, Stanzer S, Pezdirc I, Vrančić J, Šitić S, Suppan C, Balic M.

Antioxidants (Basel). 2019 Dec 11;8(12). pii: E633. doi: 10.3390/antiox8120633.

2.

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.

Müller HD, Posch F, Suppan C, Bargfrieder U, Gumpoldsberger M, Hammer R, Hauser H, Dandachi N, Prein K, Stoeger H, Lax S, Balic M.

Ann Surg Oncol. 2019 Dec;26(13):4274-4283. doi: 10.1245/s10434-019-07741-w. Epub 2019 Aug 26.

3.

Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.

Suppan C, Brcic I, Tiran V, Mueller HD, Posch F, Auer M, Ercan E, Ulz P, Cote RJ, Datar RH, Dandachi N, Heitzer E, Balic M.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1171. doi: 10.3390/cancers11081171.

4.

Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using Luminex Multiple Analyte Profiling technology for precision medicine.

Bahlas S, Damiati L, Dandachi N, Sait H, Alsefri M, Pushparaj PN.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):112-119. Epub 2018 Jun 14.

PMID:
29998825
5.

Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients.

Benezeder T, Tiran V, Treitler AAN, Suppan C, Rossmann C, Stoeger H, Cote RJ, Datar RH, Balic M, Dandachi N.

Oncotarget. 2017 Sep 30;8(54):92483-92496. doi: 10.18632/oncotarget.21426. eCollection 2017 Nov 3.

6.

Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.

Dandachi N, Tiran V, Lindenmann J, Brcic L, Fink-Neuboeck N, Kashofer K, Absenger G, Bezan A, Cote RJ, Datar R, Balic M.

Lung Cancer. 2017 Nov;113:152-157. doi: 10.1016/j.lungcan.2017.10.003. Epub 2017 Oct 9.

PMID:
29110843
7.

Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition.

Tiran V, Lindenmann J, Brcic L, Heitzer E, Stanzer S, Tabrizi-Wizsy NG, Stacher E, Stoeger H, Popper HH, Balic M, Dandachi N.

Sci Rep. 2017 Aug 30;7(1):10040. doi: 10.1038/s41598-017-09929-0.

8.

Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.

Tiran V, Stanzer S, Heitzer E, Meilinger M, Rossmann C, Lax S, Tsybrovskyy O, Dandachi N, Balic M.

PLoS One. 2017 Apr 19;12(4):e0175223. doi: 10.1371/journal.pone.0175223. eCollection 2017.

9.

Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.

Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, Loibner H, Dandachi N, Balic M.

BMC Cancer. 2015 Dec 29;15:1027. doi: 10.1186/s12885-015-2005-3.

10.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N.

Mod Pathol. 2014 Jun;27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

11.

Oxidative stress and apoptosis in a pig model of brain death (BD) and living donation (LD).

Stiegler P, Sereinigg M, Puntschart A, Bradatsch A, Seifert-Held T, Wiederstein-Grasser I, Leber B, Stadelmeyer E, Dandachi N, Zelzer S, Iberer F, Stadlbauer V.

J Transl Med. 2013 Oct 2;11:244. doi: 10.1186/1479-5876-11-244.

12.

The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Stadelmeyer E, Heitzer E, Resel M, Cerroni L, Wolf P, Dandachi N.

J Invest Dermatol. 2014 Feb;134(2):548-550. doi: 10.1038/jid.2013.338. Epub 2013 Aug 9. No abstract available.

13.

Genetic and epigenetic analysis of putative breast cancer stem cell models.

Balic M, Schwarzenbacher D, Stanzer S, Heitzer E, Auer M, Geigl JB, Cote RJ, Datar RH, Dandachi N.

BMC Cancer. 2013 Jul 24;13:358. doi: 10.1186/1471-2407-13-358.

14.

Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.

Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N, Reiner-Concin A, Kriegshäuser G.

Dis Markers. 2013;34(3):171-7. doi: 10.3233/DMA-120960.

15.

Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M, Samonigg H, Renner W, Gerger A.

Mol Genet Genomics. 2012 Sep;287(9):755-64. doi: 10.1007/s00438-012-0715-7. Epub 2012 Aug 18.

PMID:
22903472
16.

Micrometastasis: detection methods and clinical importance.

Balic M, Williams A, Dandachi N, Cote RJ.

Cancer Biomark. 2010;9(1-6):397-419. doi: 10.3233/CBM-2011-0161. Review.

PMID:
22112487
17.

COLD-HRM PCR versus conventional HRM PCR to detect the BRAF V600E mutation A real improvement?

Stadelmeyer E, Heitzer E, Wolf P, Dandachi N.

J Mol Diagn. 2011 Mar;13(2):243; author reply 244. doi: 10.1016/j.jmoldx.2010.09.005. No abstract available.

18.

Rapid and reliable detection of LINE-1 hypomethylation using high-resolution melting analysis.

Stanzer S, Balic M, Strutz J, Heitzer E, Obermair F, Hauser-Kronberger C, Samonigg H, Dandachi N.

Clin Biochem. 2010 Dec;43(18):1443-8. doi: 10.1016/j.clinbiochem.2010.09.013. Epub 2010 Sep 27.

PMID:
20883681
19.

Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells.

Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, Daidone MG, Samonigg H, Cote RJ, Dandachi N.

Appl Immunohistochem Mol Morphol. 2011 Jan;19(1):33-40. doi: 10.1097/PAI.0b013e3181ebf4e8.

PMID:
20861793
20.

PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches.

Heitzer E, Bambach I, Dandachi N, Horn M, Wolf P.

Exp Dermatol. 2010 Oct;19(10):926-8. doi: 10.1111/j.1600-0625.2010.01120.x. Epub 2010 Aug 31.

PMID:
20849535

Supplemental Content

Loading ...
Support Center